Everything below concerns certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
In the scientific literature, ipamorelin appears mainly in preclinical studies, receptor binding assays, and reviews of growth hormone secretagogues. Authors often discuss its selectivity profile alongside limitations such as small sample sizes, short study durations, and differences between species. Some papers examine pharmacokinetics and clearance, but human data are limited and not sufficient to define general clinical effects. Regulatory discussion treats the compound as an investigational or research substance rather than an approved therapy in most jurisdictions. Open questions include oral bioavailability, long-term endocrine effects, and whether selectivity observed in animals persists in humans.
Research peptides such as ipamorelin are commonly supplied as lyophilized powder and characterized by analytical certificates. Reversed-phase high-performance liquid chromatography is used to estimate purity by ultraviolet absorbance, while mass spectrometry confirms molecular identity and detects sequence-related impurities. Counterion content, water content, and residual synthesis reagents can affect the reported mass balance. A certificate of analysis may list a purity percentage, but that number depends on the analytical method and the definition of impurity peaks. Independent verification is often recommended because research supply chains vary in quality control practices.
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility class | Soluble in water and aqueous buffers | Solubility can depend on pH and salt form |
| Typical storage temperature | −20 °C or lower, desiccated | Protect from light and moisture |
| Typical analytical method | RP-HPLC with UV detection; LC-MS | Identity and purity assessment |
| Common salt form | Acetate salt | Frequently used in research supply |
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
American Solidarity Party: Peter Sonski, Connecticut school board member Approval Voting Party: Blake Huber, activist and nominee for president in 2020 Constitution Party: Randall Terry, anti-abortion activist and perennial candidate Independent American Party: Joel Skousen, survivalist and consultant Natural Law Party: Robert F. Kennedy Jr., environmental lawyer and author, the party's nominee in addition to his run as an independent before he withdrew from the race ahead of the election but was not removed from ballots Party for Socialism and Liberation: Claudia De la Cruz, political activist Prohibition Party: Michael Wood, businessman Socialist Equality Party: Joseph Kishore, writer and SEP nominee in 2020 Socialist Party USA: Bill Stodden, nonprofit executive Socialist Workers Party: Rachele Fruit, hotel worker and trade unionist
=== EC 1.14.13 With NADH or NADPH as one donor, and incorporation of one atom of oxygen into the other donor === EC 1.14.13.1: salicylate 1-monooxygenase EC 1.14.13.2: 4-hydroxybenzoate 3-monooxygenase EC 1.14.13.3: Now EC 1.14.14.9, 4-hydroxyphenylacetate 3-monooxygenase EC 1.14.13.4: melilotate 3-monooxygenase EC 1.14.13.5: imidazoleacetate 4-monooxygenase EC 1.14.13.6: orcinol 2-monooxygenase EC 1.14.13.7: phenol 2-monooxygenase EC 1.14.13.8: flavin-containing monooxygenase EC 1.14.13.9: kynurenine 3-monooxygenase EC 1.14.13.10: 2,6-dihydroxypyridine 3-monooxygenase EC 1.14.13.11: Now EC 1.14.14.91, trans-cinnamate 4-monooxygenase EC 1.14.13.12: Now EC 1.14.14.92, benzoate 4-monooxygenase EC 1.14.13.13: Now classified as EC 1.14.15.18, calcidiol 1-monooxygenase EC 1.14.13.14: trans-cinnamate 2-monooxygenase EC 1.14.13.15: Now EC 1.14.15.15, cholestanetriol 26-monooxygenase EC 1.14.13.16: cyclopentanone monooxygenase EC 1.14.13.17: Now EC 1.14.14.23, cholesterol 7α-monooxygenase EC 1.14.13.18: 4-hydroxyphenylacetate 1-monooxygenase EC 1.14.13.19: taxifolin 8-monooxygenase EC 1.14.13.20: 2,4-dichlorophenol 6-monooxygenase EC 1.14.13.21: Now EC 1.14.14.82, flavonoid 3′-monooxygenase EC 1.14.13.22: cyclohexanone monooxygenase EC 1.14.13.23: 3-hydroxybenzoate 4-monooxygenase EC 1.14.13.24: 3-hydroxybenzoate 6-monooxygenase EC 1.14.13.25: methane monooxygenase (soluble) EC 1.14.13.26: Now classified as EC 1.14.18.4, phosphatidylcholine 12-monooxygenase EC 1.14.13.27: 4-aminobenzoate 1-monooxygenase EC 1.14.13.28: Now EC 1.14.14.93, 3,9-dihydroxypterocarpan 6a-monooxygenase EC 1.14.13.29: 4-nitrophenol 2-monooxygenase EC 1.14.13.30: Now EC 1.14.14.94, leukotriene-B4 20-monooxygenase EC 1.14.13.31: 2-nitrophenol 2-monooxygenase EC 1.14.13.32: albendazole monooxygenase EC 1.14.13.33: 4-hydroxybenzoate 3-monooxygenase (NAD(P)H) EC 1.14.13.34: leukotriene-E4 20-monooxygenase EC 1.14.13.35: anthranilate 3-monooxygenase (deaminating) EC 1.14.13.36: Now EC 1.14.14.96, 5-O-(4-coumaroyl)-D-quinate 3′-monooxygenase EC 1.14.13.37: Now EC 1.14.14.97, methyltetrahydroprotoberberine 14-monooxygenase EC 1.14.13.38: anhydrotetracycline monooxygenase EC 1.14.13.39: nitric-oxide synthase EC 1.14.13.40: anthraniloyl-CoA monooxygenase EC 1.14.13.41: Now EC 1.14.14.36, tyrosine N-monooxygenase EC 1.14.13.42: The activity is covered by EC 1.14.13.68, 4-hydroxyphenylacetaldehyde oxime monooxygenase EC 1.14.13.43: questin monooxygenase EC 1.14.13.44: 2-hydroxybiphenyl 3-monooxygenase EC 1.14.13.45: Now EC 1.14.18.2, CMP-N-acetylneuraminate monooxygenase EC 1.14.13.46: (-)-menthol monooxygenase EC 1.14.13.47: Now EC 1.14.14.99, (S)-limonene 3-monooxygenase EC 1.14.13.48: Now classified as EC 1.14.14.51, (S)-limonene 6-monooxygenase EC 1.14.13.49: Now classified as EC 1.14.14.52, (S)-limonene 7-monooxygenase EC 1.14.13.50: pentachlorophenol monooxygenase EC 1.14.13.51: 6-oxocineole dehydrogenase EC 1.14.13.52: Now EC 1.14.14.88, isoflavone 3′-hydroxylase EC 1.14.13.53: Now EC 1.14.14.89, 4′-methoxyisoflavone 2′-hydroxylase EC 1.14.13.54: ketosteroid monooxygenase EC 1.14.13.55: Now EC 1.14.14.98, protopine 6-monooxygenase EC 1.14.13.56: Now EC 1.14.14.100, dihydrosanguinarine 10-monooxygenase EC 1.14.13.57: Now EC 1.14.14.101, dihydrochelirubine 12-monooxygenase EC 1.14.13.58: benzoyl-CoA 3-monooxygenase EC 1.14.13.59: L-lysine N6-monooxygenase (NADPH) EC 1.14.13.60: Now included with EC 1.14.13.100, 25-hydroxycholesterol 7α-hydroxylase EC 1.14.13.61: 2-hydroxyquinoline 8-monooxygenase EC 1.14.13.62: 4-hydroxyquinoline 3-monooxygenase EC 1.14.13.63: 3-hydroxyphenylacetate 6-hydroxylase EC 1.14.13.64: 4-hydroxybenzoate 1-hydroxylase EC 1.14.13.65: deleted EC 1.14.13.66: 2-hydroxycyclohexanone 2-monooxygenase EC 1.14.13.67: Now EC 1.14.14.55, quinine 3-monooxygenase EC 1.14.13.68: Now EC 1.14.14.37, 4-hydroxyphenylacetaldehyde oxime monooxygenase EC 1.14.13.69: alkene monooxygenase EC 1.14.13.70: Now EC 1.14.14.154, sterol 14α-demethylase EC 1.14.13.71: Now EC 1.14.14.102, N-methylcoclaurine 3′-monooxygenase EC 1.14.13.72: Now classified as EC 1.14.18.9, methylsterol monooxygenase EC 1.14.13.73: Now EC 1.14.14.103, tabersonine 16-hydroxylase EC 1.14.13.74: Now EC 1.14.14.85, 7-deoxyloganin 7-hydroxylase EC 1.14.13.75: Now EC 1.14.14.104, vinorine hydroxylase EC 1.14.13.76: Now EC 1.14.14.105, taxane 10β-hydroxylase EC 1.14.13.77: Now EC 1.14.14.106, taxane 13α-hydroxylase EC 1.14.13.78: Now EC 1.14.14.86, ent-kaurene monooxygenase EC 1.14.13.79: Now EC 1.14.14.107, ent-kaurenoic acid oxidase EC 1.14.13.80: Now classified as EC 1.14.14.53, (R)-limonene 6-monooxygenase EC 1.14.13.81: magnesium-protoporphyrin IX monomethyl ester (oxidative) cyclase EC 1.14.13.82: vanillate monooxygenase EC 1.14.13.83: precorrin-3B synthase EC 1.14.13.84: 4-hydroxyacetophenone monooxygenase EC 1.14.13.85: Now EC 1.14.14.135, glyceollin synthase EC 1.14.13.86: The activity is covered by EC 1.14.14.87, 2-hydroxyisoflavanone synthase EC 1.14.13.87: Now EC 1.14.14.140, licodione synthase] EC 1.14.13.88: Now EC 1.14.14.81, flavanoid 3,5-hydroxylase EC 1.14.13.89: Now EC 1.14.14.90, isoflavone 2-hydroxylase EC 1.14.13.90: Now EC 1.14.15.21, zeaxanthin epoxidase EC 1.14.13.91: Now EC 1.14.14.136, deoxysarpagine hydroxylase EC 1.14.13.92: phenylacetone monooxygenase EC 1.14.13.93: Now EC 1.14.14.137, (+)-abscisic acid 8-hydroxylase EC 1.14.13.94: Now EC 1.14.14.138, lithocholate 6β-hydroxylase EC 1.14.13.95: Now included with EC 1.14.14.139, 5β-cholestane-3α,7α-diol 12α-hydroxylase EC 1.14.13.96: Now EC 1.14.14.139, 5β-cholestane-3α,7α-diol 12α-hydroxylase EC 1.14.13.97: Now EC 1.14.14.57, taurochenodeoxycholate 6α-hydroxylase EC 1.14.13.98: Now EC 1.14.14.25, cholesterol 24-hydroxylase EC 1.14.13.99: Now EC 1.14.14.26, 24-hydroxycholesterol 7α-hydroxylase EC 1.14.13.100: Now classified as EC 1.14.14.29, 25/26-hydroxycholesterol 7α-hydroxylase EC 1.14.13.101: senecionine N-oxygenase EC 1.14.13.102: Now EC 1.14.14.141, psoralen synthase EC 1.14.13.103: Now EC 1.14.14.142, 8-dimethylallylnaringenin 2-hydroxylase EC 1.14.13.104: Now EC 1.14.14.143, (+)-menthofuran synthase EC 1.14.13.105: monocyclic monoterpene ketone monooxygenase EC 1.14.13.106: now classified as EC 1.14.15.39, epi-isozizaene 5-monooxygenase. EC 1.14.13.107: limonene 1,2-monooxygenase EC 1.14.13.108: Now EC 1.14.14.144, abieta-7,13-diene hydroxylase EC 1.14.13.109: Now EC 1.14.14.145, abieta-7,13-dien-18-ol hydroxylase EC 1.14.13.110: Now EC 1.14.14.146, geranylgeraniol 18-hydroxylase EC 1.14.13.111: methanesulfonate monooxygenase EC 1.14.13.112: Now EC 1.14.14.147, 3-epi-6-deoxocathasterone 23-monooxygenase EC 1.14.13.113: FAD-dependent urate hydroxylase EC 1.14.13.114: 6-hydroxynicotinate 3-monooxygenase EC 1.14.13.115: Now EC 1.14.14.148, angelicin synthase EC 1.14.13.116: Now EC 1.14.14.174, geranylhydroquinone 3-hydroxylase EC 1.14.13.117: Now EC 1.14.14.39, isoleucine N-monooxygenase EC 1.14.13.118: Now EC 1.14.14.38, valine N-monooxygenase EC 1.14.13.119: Now EC 1.14.14.149, 5-epiaristolochene 1,3-dihydroxylase EC 1.14.13.120: Now EC 1.14.14.150, costunolide synthase EC 1.14.13.121: Now EC 1.14.14.151, premnaspirodiene oxygenase EC 1.14.13.122: chlorophyllide-a oxygenase EC 1.14.13.123: Now EC 1.14.14.95, germacrene A hydroxylase EC 1.14.13.124: now classified as EC 1.14.14.40, phenylalanine N-monooxygenase EC 1.14.13.125: Now EC 1.14.14.156, tryptophan N-monooxygenase EC 1.14.13.126: Now EC 1.14.15.16, vitamin D3 24-hydroxylase EC 1.14.13.127: 3-(3-hydroxyphenyl)propanoate hydroxylase EC 1.14.13.128: 7-methylxanthine demethylase EC 1.14.13.129: Now EC 1.14.15.24, β-carotene 3-hydroxylase EC 1.14.13.130: pyrrole-2-carboxylate monooxygenase EC 1.14.13.131: dimethyl-sulfide monooxygenase EC 1.14.13.132: Now EC 1.14.14.17, squalene monooxygenase EC 1.14.13.133: Now EC 1.14.15.32, pentalenene oxygenase EC 1.14.13.134: Now EC 1.14.14.152, β-amyrin 11-oxidase EC 1.14.13.135: 1-hydroxy-2-naphthoate hydroxylase EC 1.14.13.136: Now EC 1.14.14.87, 2-hydroxyisoflavanone synthase EC 1.14.13.137: Now EC 1.14.14.153, indole-2-monooxygenase EC 1.14.13.138: Now EC 1.14.14.157, indolin-2-one monooxygenase EC 1.14.13.139: Now EC 1.14.14.109, 3-hydroxyindolin-2-one monooxygenase EC 1.14.13.140: Now EC 1.14.14.110, 2-hydroxy-1,4-benzoxazin-3-one monooxygenase. EC 1.14.13.141: Now EC 1.14.15.29, cholest-4-en-3-one 26-monooxygenase [(25S)-3-oxocholest-4-en-26-oate forming] EC 1.14.13.142: Now EC 1.14.15.30, 3-ketosteroid 9α-monooxygenase EC 1.14.13.143: Now EC 1.14.14.76 ent-isokaurene C2/C3-hydroxylase EC 1.14.13.144: Now EC 1.14.14.111, 9β-pimara-7,15-diene oxidase EC 1.14.13.145: Now EC 1.14.14.112, ent-cassa-12,15-diene 11-hydroxylase EC 1.14.13.146: taxoid 14β-hydroxylase EC 1.14.13.147: Now EC 1.14.14.182, taxoid 7β-hydroxylase EC 1.14.13.148: trimethylamine monooxygenase EC 1.14.13.149: phenylacetyl-CoA 1,2-epoxidase EC 1.14.13.150: Now EC 1.14.14.113, α-humulene 10-hydroxylase EC 1.14.13.151: Now EC 1.14.14.84, linalool 8-monooxygenase EC 1.14.13.152: Now EC 1.14.14.83, geraniol 8-hydroxylase EC 1.14.13.153: (+)-sabinene 3-hydroxylase EC 1.14.13.154: erythromycin 12-hydroxylase EC 1.14.13.155: α-pinene monooxygenase EC 1.14.13.156: Now EC 1.14.14.133, 1,8-cineole 2-endo-monooxygenase EC 1.14.13.157: Now EC 1.14.14.56, 1,8-cineole 2-exo-monooxygenase EC 1.14.13.158: Now EC 1.14.14.114, amorpha-4,11-diene 12-monooxygenase EC 1.14.13.159: Now EC 1.14.14.24, vitamin D 25-hydroxylase EC 1.14.13.160: (2,2,3-trimethyl-5-oxocyclopent-3-enyl)acetyl-CoA 1,5-monooxygenase EC 1.14.13.161: (+)-camphor 6-exo-hydroxylase EC 1.14.13.162: Now EC 1.14.14.108, 2,5-diketocamphane 1,2-monooxygenase EC 1.14.13.163: 6-hydroxy-3-succinoylpyridine 3-monooxygenase EC 1.14.13.164: withdrawn: see EC 1.13.11.65, carotenoid isomerooxygenase EC 1.14.13.165: Now classified as EC 1.14.14.47, nitric-oxide synthase (flavodoxin) EC 1.14.13.166: 4-nitrocatechol 4-monooxygenase EC 1.14.13.167: 4-nitrophenol 4-monooxygenase EC 1.14.13.168: indole-3-pyruvate monooxygenase EC 1.14.13.169: Now EC 1.14.18.5, sphingolipid C4-monooxygenase EC 1.14.13.170: pentalenolactone D synthase EC 1.14.13.171: neopentalenolactone D synthase EC 1.14.13.172: salicylate 5-hydroxylase EC 1.14.13.173: Now EC 1.14.14.115, 11-oxo-β-amyrin 30-oxidase EC 1.14.13.174: Now EC 1.14.14.116, averantin hydroxylase EC 1.14.13.175: Now EC 1.14.14.117, aflatoxin B synthase EC 1.14.13.176: Now EC 1.14.14.118, tryprostatin B 6-hydroxylase EC 1.14.13.177: Now EC 1.14.14.119, fumitremorgin C monooxygenase EC 1.14.13.178: methylxanthine N1-demethylase EC 1.14.13.179: methylxanthine N3-demethylase EC 1.14.13.180: aklavinone 12-hydroxylase EC 1.14.13.181: 13-deoxydaunorubicin hydroxylase EC 1.14.13.182: 2-heptyl-3-hydroxy-4(1H)-quinolone synthase EC 1.14.13.183: Now EC 1.14.14.120, dammarenediol 12-hydroxylase EC 1.14.13.184: Now EC 1.14.14.121, protopanaxadiol 6-hydroxylase EC 1.14.13.185: Now EC 1.14.15.33, pikromycin synthase EC 1.14.13.186: Now EC 1.14.15.34, 20-oxo-5-O-mycaminosyltylactone 23-monooxygenase EC 1.14.13.187: L-evernosamine nitrososynthase EC 1.14.13.188: Now EC 1.14.15.35, 6-deoxyerythronolide B hydroxylase EC 1.14.13.189: 5-methyl-1-naphthoate 3-hydroxylase EC 1.14.13.190: Now EC 1.14.14.175, ferruginol synthase EC 1.14.13.191: Now EC 1.14.14.70, ent-sandaracopimaradiene 3-hydroxylase EC 1.14.13.192: Now EC 1.14.14.122, oryzalexin E synthase EC 1.14.13.193: Now EC 1.14.14.123, oryzalexin D synthase EC 1.14.13.194: Now EC 1.14.14.78, phylloquinone ω-hydroxylase EC 1.14.13.195: L-ornithine N5-monooxygenase (NADPH) EC 1.14.13.196: L-ornithine N5-monooxygenase [NAD(P)H] EC 1.14.13.197: Now EC 1.14.14.124, dihydromonacolin L hydroxylase EC 1.14.13.198: Now EC 1.14.14.125, monacolin L hydroxylase EC 1.14.13.199: Now EC 1.14.14.79, docosahexaenoic acid ω-hydroxylase EC 1.14.13.200: tetracenomycin A2 monooxygenase-dioxygenase EC 1.14.13.201: Now EC 1.14.14.126, β-amyrin 28-monooxygenase EC 1.14.13.202: Now EC 1.14.14.127, methyl farnesoate epoxidase EC 1.14.13.203: Now EC 1.14.14.128, farnesoate epoxidase EC 1.14.13.204: Now EC 1.14.14.129, long-chain acyl-CoA ω-monooxygenase EC 1.14.13.205: Now EC 1.14.14.80, long-chain fatty acid ω-monooxygenase EC 1.14.13.206: Now EC 1.14.14.130, laurate 7-monooxygenase EC 1.14.13.207: Now EC 1.14.14.31, ipsdienol synthase EC 1.14.13.208: benzoyl-CoA 2,3-epoxidase EC 1.14.13.209: salicyloyl-CoA 5-hydroxylase EC 1.14.13.210: 4-methyl-5-nitrocatechol 5-monooxygenase EC 1.14.13.211: rifampicin monooxygenase EC 1.14.13.212: 1,3,7-trimethyluric acid 5-monooxygenase EC 1.14.13.213: Now EC 1.14.14.131, bursehernin 5-monooxygenase EC 1.14.13.214: Now EC 1.14.14.132, (–)-4′-demethyl-deoxypodophyllotoxin 4-hydroxylase EC 1.14.13.215: protoasukamycin 4-monooxygenase EC 1.14.13.216: asperlicin C monooxygenase EC 1.14.13.217: protodeoxyviolaceinate monooxygenase EC 1.14.13.218: 5-methylphenazine-1-carboxylate 1-monooxygenase EC 1.14.13.219: resorcinol 4-hydroxylase (NADPH) EC 1.14.13.220: resorcinol 4-hydroxylase (NADH) EC 1.14.13.221: Now EC 1.14.15.28, cholest-4-en-3-one 26-monooxygenase [(25R)-3-oxocholest-4-en-26-oate forming] EC 1.14.13.222: aurachin C monooxygenase/isomerase EC 1.14.13.223: 3-hydroxy-4-methylanthranilyl-[aryl-carrier protein] 5-monooxygenase EC 1.14.13.224: violacein synthase EC 1.14.13.225: F-actin monooxygenase EC 1.14.13.226: acetone monooxygenase (methyl acetate-forming) EC 1.14.13.227: propane 2-monooxygenase EC 1.14.13.228: jasmonic acid 12-hydroxylase EC 1.14.13.229: tert-butyl alcohol monooxygenase EC 1.14.13.230: butane monooxygenase (soluble) EC 1.14.13.231: tetracycline 11a-monooxygenase EC 1.14.13.232: 6-methylpretetramide 4-monooxygenase EC 1.14.13.233: 4-hydroxy-6-methylpretetramide 12a-monooxygenase EC 1.14.13.234: 5a,11a-dehydrotetracycline 5-monooxygenase EC 1.14.13.235: indole-3-acetate monooxygenase EC 1.14.13.236: toluene 4-monooxygenase EC 1.14.13.237: aliphatic glucosinolate S-oxygenase EC 1.14.13.238: dimethylamine monooxygenase EC 1.14.13.239: carnitine monooxygenase EC 1.14.13.240: 2-polyprenylphenol 6-hydroxylase EC 1.14.13.241: 5-pyridoxate monooxygenase EC 1.14.13.242: 3-hydroxy-2-methylpyridine-5-carboxylate monooxygenase EC 1.14.13.243: toluene 2-monooxygenase EC 1.14.13.244: phenol 2-monooxygenase (NADH) EC 1.14.13.245: assimilatory dimethylsulfide S-monooxygenase EC 1.14.13.246: 4β-methylsterol monooxygenase EC 1.14.13.247: stachydrine N-demethylase
In Mexico, Applied Biosystems collaborated with the National Institute of Genomic Medicine of Mexico (Instituto Nacional de Medicina Genomica or INMEGEN), and established an Applied Biosystems Sequencing and Genotyping Unit at INMEGEN. In 2006, Applied Biosystems acquired the Research Products Division of Ambion, a supplier of RNA-based reagents and products. That year, with the Influenza A Subtype H5N1 "avian flu" strain scare, the company launched a global initiative to identify and track such infectious diseases. In 2006, Applied Biosystems also acquired Agencourt Personal Genomics, located in Beverly, MA, to commercialize Agencourt's SOLiD sequencing system. In 2007, ABI Solid Sequencing, a next-gen DNA sequencing platform, was announced. Mark Stevenson was appointed president and chief operating officer of Applied Biosystems. In November 2008, Applied Biosystems merged with Invitrogen, forming Life Technologies, which was acquired by Thermo Fisher Scientific in 2014.
== Isolable thioketenes == Thioketenes can be stabilized by either steric protection or by electronic effects. Thus, di-tert-butyl thioketene is easily isolated and air-stable. Several examples have been characterized by X-ray crystallography. The C=S distance is 157 pm and the C=C distance is 124 pm, both bonds being suitable for the C=C=S assignment. The violet color characteristic of thioketenes indicates the small HOMO–LUMO gap. Bis(trifluoromethyl)thioketene ((CF3)2C=C=S) is an example of an electronically stabilized thioketene.
Sources: en.wikipedia.org
Methyl jasmonate is volatile and can therefore activate systemic acquired resistance in neighbouring plants, preparing their defences for attack. These signalling events are analogous to the cytokine-mediated inflammatory immune response in animals. When the inflammatory response is activated in animals, MAPKs are activated which in turn activate phospholipases. Lipids in the membrane are converted to arachidonic acid and then to prostaglandins, which are analogs of jasmonic acid. Both pathways can be inhibited by suramin. Early experiments with radiolabelled systemin in tomato demonstrated that it is transported through the phloem sap in tomato plants and was therefore thought to be the systemic signal that activated systemic acquired resistance. This view was challenged by grafting experiments which showed that mutants deficient in jasmonic acid biosynthesis and perception were unable to activate systemic acquired resistance. It is now thought that jasmonic acid is the systemic signal and that systemin upregulates the pathways for jasmonic acid synthesis.
Some crashed on flight decks, but the majority ditched into the sea. Some pilots intentionally went down in groups to facilitate rescue, and more ditched individually either in a controlled landing with a few gallons of fuel left or in a crash after their engines ran dry. Approximately three-quarters of the crews were rescued from the sea, either that night from crash locations within the task forces, or over the next few days for those further out, as search planes and destroyers criss-crossed the ocean looking for them.
=== Society === Nigeria has been generating most of its revenue from oil industry for the past 30 years. However, since petroleum industry has appeared, many pollution problems have risen in Nigeria. The major problem was caused by oil spills, occurring during usual operations. From 1976 to 1988, 2000 oil spillages happened in Nigeria and more than two million barrels of bonny light oil were released to the community during this period. Additionally, break of oil pipelines, erosion of flow and trunk lines, and hose failure are the causes of oil spills. Consequently, both the aquatic milieu and environment had detrimental impacts by them. These ecosystems are key element in agricultural productivity and main source for Nigerians, inhabiting in the oil-producing areas, to live. Therefore, some activists in Nigeria have spoiled pipelines, and key infrastructures which are related to crude oil and export flows are usually targeted. As a result, the issue related to oil effusion in Nigeria has been exacerbated. In Nigeria, microbial seeding is being considered instead of mechanical ways by the main oil companies for the purpose of cleaning up oil spills.
Pseudopeptidoglycan (also known as pseudomurein; PPG hereafter) is a major cell wall component of some Archaea that differs from bacterial peptidoglycan in chemical structure, but resembles bacterial peptidoglycan in function and physical structure. Pseudopeptidoglycan, in general, is only present in a few methanogenic archaea. The basic components are N-acetylglucosamine and N-acetyltalosaminuronic acid (bacterial peptidoglycan containing N-acetylmuramic acid instead), which are linked by β-1,3-glycosidic bonds. Lysozyme, a host defense mechanism present in human secretions (e.g. saliva and tears) breaks β-1,4-glycosidic bonds to degrade peptidoglycan. However, because pseudopeptidoglycan has β-1,3-glycosidic bonds, lysozyme is ineffective. It was thought from these large differences in cell wall chemistry that archaeal cell walls and bacterial cell walls have not evolved from a common ancestor but are only the result of a convergent evolution, but recent structural work has revealed deeper homology. No archaeal enzymes are known that cleave the β-1,3-glycosidic bonds in pseudopeptidoglycan, but it can be degraded by pseudomurein endoisopeptidase encoded by two prophages. The pseudomurein endoisopeptidases function by cleaving the peptide links between adjacent pseudopeptidoglycan strands.
Because PCR amplifies the regions of DNA that it targets, PCR can be used to analyze extremely small amounts of sample. This is often critical for forensic analysis, when only a trace amount of DNA is available as evidence. PCR may also be used in the analysis of ancient DNA that is tens of thousands of years old. These PCR-based techniques have been successfully used on animals, such as a forty-thousand-year-old mammoth, and also on human DNA, in applications ranging from the analysis of Egyptian mummies to the identification of a Russian tsar and the body of English king Richard III. Quantitative PCR or real-time PCR (qPCR not to be confused with RT-PCR) methods allow the estimation of the amount of a given sequence present in a sample—a technique often applied to quantitatively determine levels of gene expression. The MIQE guidelines written by professors Stephen Bustin, Michael Pfaffl, Mikael Kubista and colleagues outline how qPCR experiments shall be performed and the results reported. Quantitative PCR is an established tool for DNA quantification that measures the accumulation of DNA product after each round of PCR amplification. qPCR allows the quantification and detection of a specific DNA sequence in real time since it measures concentration while the synthesis process is taking place. There are two methods for simultaneous detection and quantification. The first method consists of using fluorescent dyes that are retained nonspecifically in between the double strands.
Sources: en.wikipedia.org
Purity is commonly estimated by reversed-phase high-performance liquid chromatography with ultraviolet detection. Mass spectrometry is used to confirm identity and to detect sequence-related impurities. Reported percentages depend on the method and the impurity threshold used.
Lyophilized powder is usually kept frozen, desiccated, and protected from light. Reconstituted solutions are often divided into aliquots and stored at very low temperature to limit freeze-thaw cycles. Specific conditions should follow the supplier's certificate of analysis and the assay requirements.
Much of the evidence comes from animal models and cell-based assays rather than large human trials. Small sample sizes, short follow-up, and differences in dosing or route make comparisons difficult. Questions about long-term effects and human relevance remain open.
不是。它属于人工合成的五肽，设计上模拟胃饥饿素受体的部分作用，但不存在于人体天然激素谱中。